Clinical and Molecular Hepatology (Clin Mol Hepatol, CMH)

Review

Bioactive metabolites: A clue to the link between MASLD and CKD?

Wen-Ying Chen, Jia-Hui Zhang, Li-Li Chen, Christopher D. Byrne, Giovanni Targher, Liang Luo, Yan Ni, Ming-Hua Zheng, Dan-Qin Sun

Clin Mol Hepatol. 2025;31(1):56-73. Published online October 21, 2024

DOI: https://doi.org/10.3350/cmh.2024.0782

View: 1367 Download: 165

Original Article

Gut microbiome and metabolome signatures in liver cirrhosis-related complications

Satya Priya Sharma, Haripriya Gupta, Goo-Hyun Kwon, Sang Yoon Lee, Seol Hee Song, Jeoung Su Kim, Jeong Ha Park, Min Ju Kim, Dong-Hoon Yang, Hyunjoon Park, Sung-Min Won, Jin-Ju Jeong, Ki-Kwang Oh, Jung A Eom, Kyeong Jin Lee, Sang Jun Yoon, Young Lim Ham, Gwang Ho Baik, Dong Joon Kim, Ki Tae Suk

Clin Mol Hepatol. 2024;30(4):845-862. Published online July 25, 2024

DOI: https://doi.org/10.3350/cmh.2024.0349

View: 4495 Download: 968 Web of Science: 5 Crossref: 4

Snapshot

Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations

Xinyi Lu, Rui Yang, Yu Chen, Daozhen Chen

Clin Mol Hepatol. 2024;30(3):582-584. Published online December 29, 2023

DOI: https://doi.org/10.3350/cmh.2023.0555

View: 8505 Download: 99

Microbiome and metabolomics in alcoholic liver disease

Raja Ganesan, Ki Tae Suk

Clin Mol Hepatol. 2022;28(3):580-582. Published online July 1, 2022

DOI: https://doi.org/10.3350/cmh.2022.0171

View: 6109 Download: 172 Web of Science: 13 Crossref: 10

Special topic: Alcoholic liver diseases The 14th International Symposium on Alcoholic Liver and Pancreatic Diseases and Cirrhosis (ISALPDC)

Nonalcoholic fatty liver disease and alcohol-related liver disease: From clinical aspects to pathophysiological insights

Kenichi Ikejima, Kazuyoshi Kon, Shunhei Yamashina

Clin Mol Hepatol. 2020;26(4):728-735. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0202

View: 7519 Download: 202 Web of Science: 27 Crossref: 26

Predictors of steroid non-response and new approaches in severe alcoholic hepatitis

Shiv Kumar Sarin, Shvetank Sharma

Clin Mol Hepatol. 2020;26(4):639-651. Published online October 1, 2020

DOI: https://doi.org/10.3350/cmh.2020.0196

View: 9776 Download: 264 Web of Science: 12 Crossref: 13

Review

Fecal microbiota transplantation in alcohol related liver diseases

Saggere Muralikrishna Shasthry

Clin Mol Hepatol. 2020;26(3):294-301. Published online June 23, 2020

DOI: https://doi.org/10.3350/cmh.2020.0057

View: 8249 Download: 238 Web of Science: 29 Crossref: 32

Microbiota, a key player in alcoholic liver disease

Anne-Marie Cassard, Dragos Ciocan

Clin Mol Hepatol. 2018;24(2):100-107. Published online December 22, 2017

DOI: https://doi.org/10.3350/cmh.2017.0067

View: 12940 Download: 543 Web of Science: 73 Crossref: 73

Microbiome-Centered Therapies for the Management of Metabolic Dysfunction-Associated Steatotic Liver Disease

Huma Saeed, Luis Antonio Díaz, Antonio Gil-Gómez, Jeremy Burton, Jasmohan Bajaj, Manuel Romero-Gomez, Marco Arrese, Juan Pablo Arab, Mohammad Qasim Khan

Received September 13, 2024 Accepted November 20, 2024

DOI: https://doi.org/10.3350/cmh.2024.0811 [Accepted]

View: 2449 Download: 223 Crossref: 1

Review Article

Gut microbiota-mediated gut-liver axis: a breakthrough point for understanding and treating liver cancer

Chenyang Li, Chujun Cai, Chendong Wang, Xiaoping Chen, Bixiang Zhang, Zhao Huang

Received September 30, 2024 Accepted December 6, 2024

DOI: https://doi.org/10.3350/cmh.2024.0857 [Accepted]

View: 817 Download: 109

Snapshot

Interventions Targeting the Gut-Liver Axis: A Potential Treatment Strategy for MASLD

Pingping Jin, Xinyi Lu, Daozhen Chen, Yu Chen

Received December 2, 2024 Accepted February 4, 2025

DOI: https://doi.org/10.3350/cmh.2024.1090 [Accepted]

View: 139 Download: 23

Correspondence

GOLM1 and Bile Acid Synthesis: Correspondence to the Editorial “Bridging the Gap: The GOLM1-OPN-ABCG5 Axis in MASH and Gallstone Disease”

Yi-Tong Li, Wei-Qing Shao, Zhen-Mei Chen, Jing Lin, Jin-Hong Chen

Received February 3, 2025 Accepted February 12, 2025

DOI: https://doi.org/10.3350/cmh.2025.0120 [Accepted]

View: 5 Download: 0

1 |

Viewed By 6283	MAFLD: How is it different from NAFLD?
Viewed By 5060	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Viewed By 4861	Global incidence and prevalence of nonalcoholic fatty liver disease
Viewed By 3502	Gut microbiome and metabolome signatures in liver cirrhosis-related complications
Viewed By 3119	Global prevalence of metabolic dysfunction-associated fatty liver disease-related hepatocellular carcinoma: A systematic review and meta-analysis

Cited By 287	Assessing the performance of ChatGPT in answering questions regarding cirrhosis and hepatocellular carcinoma
Cited By 239	Global incidence and prevalence of nonalcoholic fatty liver disease
Cited By 161	MAFLD: How is it different from NAFLD?
Cited By 85	Non-alcoholic fatty liver disease: Definition and subtypes
Cited By 81	Pathogenesis and treatment of non-alcoholic steatohepatitis and its fibrosis

Search